Clinical Trial Update: A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD [Phase 1]

View source ↗

Summary

Phase 1 study of EDP 305 in healthy subjects and individuals with presumptive non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• EDP-305

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Presumptive NAFLD | Phase 1 | Status: COMPLETED